Nuvectis Pharma Inc.
NVCT
We are a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. We seek to develop drug candidates in the precision medicine space, and our processes for selection and clinical development of drug candidates are based on scientific data into cancer-promoting factors, as well…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$50M
▼ -39.2% YoY
Op. Margin
–
ROIC
-97.83%
▼ -11.8pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$40M
▼ -30.7% YoY
Net Debt
-$141M
Net Cash Position
Cash & Equiv.
$141M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with NVCT
Held by ETFs
NVCT is in 5 US ETFs. The largest of them, with NVCT's weight in each:
Nuvectis Pharma (NVCT) in two numbers
Questions about Nuvectis Pharma
Does Nuvectis Pharma (NVCT) pay a dividend?
No. Nuvectis Pharma (NVCT) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 30 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in NVCT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing NVCT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.